New International Marketing Director for Britannia Pharmaceuticals Ltd

30 March 2013

Britannia Pharmaceuticals (part of the STADA Arzneimittel group of companies) has appointed Robert Wood as Marketing Director, for international markets.    

Robert was previously Director Partners, EMEA at Britannia and as part of the company’s expansion takes up the new position of Marketing Director with immediate effect.

Robert has 15 years experience in  the life science and pharmaceutical industries and prior to joining Britannia in early 2011, began his career at Johnson & Johnson Neurosurgical.  He has also held the position of Business Unit Director, Pharmaceuticals at International SOS and Vice President of  Business Development at Optasia Medical. Robert holds an MBA from Kingston Business School, London and a BSc (Hons) in  Biology/Biochemistry from Royal Holloway, University of London. 

‘I am delighted to be continuing to work with Britannia Pharmaceuticals in this new global role, particularly at this incredibly interesting time for the APO-go therapy. The initiation of clinical trials to increase the evidence base for both motor and non-motor effects of APO-go in Parkinson’s disease and the development of new delivery devices, mean APO-go will provide an excellent treatment option for many more people with Parkinson’s.’

Britannia  Pharmaceuticals has been working in the field of Parkinson’s disease (PD) for  over thirty years.  Its APO-go product range for PD is licensed in almost 40 countries globally.


Back to news